Efficient Synthesis with Green Chemistry Approach of Novel Pharmacophores of Imidazole-Based Hybrids for Tumor Treatment: Mechanistic Insights from In Situ to In Silico
作者:Majid Khan、Syed Raza Shah、Faizullah Khan、Sobia Ahsan Halim、Shaikh Mizanoor Rahman、Mohammad Khalid、Ajmal Khan、Ahmed Al-Harrasi
DOI:10.3390/cancers14205079
日期:——
studies that revealed that compounds 7, 3, 11, 10, 4, and 9 for CA-IX and 1, 2, and 11 for CA-II are competitive inhibitors with dissociation constant (Ki) in the range of 7.32-17.02 µM. Furthermore, the in situ cytotoxicity of these compounds was investigated in the human breast cancer cell line MDA-MB-231 and compared with the normal human breast cell line, MCF-10A. Compound 5 showed excellent anticancer/cytotoxic
基于咪唑的嘧啶杂化物被认为是药物化学中一类非凡的化合物。在这里,我们报告了 11 种基于咪唑的嘧啶杂合体 (1-11) 的抗癌生物活性,这些杂合体特异性靶向胞质碳酸酐酶 (CAs) 同工酶,包括人 CA-II 和人 CA-IX(hCA-II 和 hCA-IX) . 通过使硝基咪唑的芳族硝基取代与碳亲核试剂反应,使用高度环保的水性方法形成碳-碳键。体外结果表明,这类新化合物 (1-11) 包括显着的 hCA IX 抑制剂,IC50 值在 9.6 ± 0.2-32.2 ± 1.0 µM 范围内,而 hCA II 显示 IC50 值在 11.6 ± 0.2 范围内-31.1 ± 1.3 µM。化合物 2 (IC50 = 12.3 ± 0.1 µM) 显示对 hCA-II 的选择性抑制,而 7、8、和 10 (IC50 = 9.6-32.2 µM) 对 hCA-IX 具有选择性。通过体外动力学研究研究了作用机制,结果表明化合物